NEW YORK (GenomeWeb) – PreCyte has received a one-year, $300,000 grant from the National Cancer Institute to develop a blood-based lung cancer diagnostic based on its core Indicator Cell Assay Platform (ICAP) technology.

ICAP was originally developed at the Institute for Systems Biology in the lab of company Co-founder John Aitchison and involves the use of cultured cells as biosensors, exposing them to patient serum and analyzing the transcriptional effect.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.